Literature DB >> 26039213

Favorable NK cell activity after haploidentical hematopoietic stem cell transplantation in stage IV relapsed Ewing's sarcoma patients.

P Schlegel1, T Feuchtinger1, C Nitschke-Gérard1, U J Eva Seidel1, A-M Lang1, C Kyzirakos1, H-M Teltschik1, M Ebinger1, M Schumm1, E Koscielniak2, R Handgretinger1, P Lang1.   

Abstract

Natural killer (NK) cell activity has been shown to have potential activity against Ewing's sarcoma (EWS) especially in tumors with low HLA I expression and high NKG2D expression. Two patients with metastatic relapsed and primary metastatic stage IV EWS who had received two courses of high dose chemotherapy with autologous stem cell rescue were transplanted from a haploidentical parental stem cell donor. Patients are alive in ongoing CR for 10.2 and 3.4 years now. Post transplant local second and first relapses were treated successfully in both patients. In vivo IL-2 stimulation not only increased the number and activity of effector cells in one patient but was also associated with severe GvHD. In vitro studies demonstrated high NK cell activity against K562 and relevant activity against EWS cell line A673 post transplant. NK activity was enhanced by cytokine prestimulation as well as by EWS targeting anti-GD2 Ab. Haploidentical hematopoietic stem cell transplantation (HSCT) might contribute to long-term survival by NK cell-mediated effect exerted by donor-derived NK cells. Local tumor recurrence was manageable in both high-risk patients indicating systemic immune control preventing subsequent metastasizing. The efficacy of haploidentical HSCT, cytokine application and tumor targeting antibodies for the use of Ab-dependent cellular cytotoxicity needs evaluation in clinical trials.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26039213     DOI: 10.1038/bmt.2015.100

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  42 in total

1.  Time-resolved fluorometric assay for natural killer activity using target cells labelled with a fluorescence enhancing ligand.

Authors:  K Blomberg; R Hautala; J Lövgren; V M Mukkala; C Lindqvist; K Akerman
Journal:  J Immunol Methods       Date:  1996-06-21       Impact factor: 2.303

2.  Interleukin 15 provides relief to CTLs from regulatory T cell-mediated inhibition: implications for adoptive T cell-based therapies for lymphoma.

Authors:  Serena K Perna; Biagio De Angelis; Daria Pagliara; Sayyeda T Hasan; Lan Zhang; Aruna Mahendravada; Helen E Heslop; Malcolm K Brenner; Cliona M Rooney; Gianpietro Dotti; Barbara Savoldo
Journal:  Clin Cancer Res       Date:  2012-11-13       Impact factor: 12.531

3.  Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value.

Authors:  Loredana Ruggeri; Antonella Mancusi; Marusca Capanni; Elena Urbani; Alessandra Carotti; Teresa Aloisi; Martin Stern; Daniela Pende; Katia Perruccio; Emanuela Burchielli; Fabiana Topini; Erika Bianchi; Franco Aversa; Massimo F Martelli; Andrea Velardi
Journal:  Blood       Date:  2007-03-19       Impact factor: 22.113

Review 4.  Natural killer cell alloreactivity for leukemia therapy.

Authors:  Loredana Ruggeri; Antonella Mancusi; Katia Perruccio; Emanuela Burchielli; Massimo F Martelli; Andrea Velardi
Journal:  J Immunother       Date:  2005 May-Jun       Impact factor: 4.456

5.  Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma.

Authors:  Fariba Navid; Paul M Sondel; Raymond Barfield; Barry L Shulkin; Robert A Kaufman; Jim A Allay; Jacek Gan; Paul Hutson; Songwon Seo; Kyungmann Kim; Jacob Goldberg; Jacquelyn A Hank; Catherine A Billups; Jianrong Wu; Wayne L Furman; Lisa M McGregor; Mario Otto; Stephen D Gillies; Rupert Handgretinger; Victor M Santana
Journal:  J Clin Oncol       Date:  2014-04-07       Impact factor: 44.544

6.  Multiple defects of the antigen-processing machinery components in human neuroblastoma: immunotherapeutic implications.

Authors:  Lizzia Raffaghello; Ignazia Prigione; Paola Bocca; Fabio Morandi; Marta Camoriano; Claudio Gambini; Xinhui Wang; Soldano Ferrone; Vito Pistoia
Journal:  Oncogene       Date:  2005-07-07       Impact factor: 9.867

7.  Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma.

Authors:  Thorsten Simon; Barbara Hero; Andreas Faldum; Rupert Handgretinger; Martin Schrappe; Dietrich Niethammer; Frank Berthold
Journal:  J Clin Oncol       Date:  2004-09-01       Impact factor: 44.544

8.  Recognition of neuroectodermal tumors by melanoma-specific cytotoxic T lymphocytes: evidence for antigen sharing by tumors derived from the neural crest.

Authors:  P Shamamian; M Mancini; Y Kawakami; N P Restifo; S A Rosenberg; S L Topalian
Journal:  Cancer Immunol Immunother       Date:  1994-08       Impact factor: 6.968

9.  A pilot study of low-dose recombinant interleukin-2 for acute lymphoblastic malignancy after unmanipulated allogeneic blood and marrow transplantation.

Authors:  K-Y Liu; Y-H Chen; D-H Liu; L-P Xu; X-J Huang
Journal:  Bone Marrow Transplant       Date:  2008-07-21       Impact factor: 5.483

Review 10.  Allogeneic transplantation as anticancer immunotherapy.

Authors:  Simrit Parmar; David S Ritchie
Journal:  Curr Opin Immunol       Date:  2014-02-15       Impact factor: 7.486

View more
  9 in total

1.  Targeting Ewing sarcoma with activated and GD2-specific chimeric antigen receptor-engineered human NK cells induces upregulation of immune-inhibitory HLA-G.

Authors:  Sareetha Kailayangiri; Bianca Altvater; Christian Spurny; Silke Jamitzky; Sonja Schelhaas; Andreas H Jacobs; Constanze Wiek; Katharina Roellecke; Helmut Hanenberg; Wolfgang Hartmann; Heinz Wiendl; Susann Pankratz; Jutta Meltzer; Nicole Farwick; Lea Greune; Maike Fluegge; Claudia Rossig
Journal:  Oncoimmunology       Date:  2016-10-28       Impact factor: 8.110

2.  Haploidentical HCT using an αβ T-cell-depleted graft with targeted αβ(+) cells by add-back after a reduced intensity preparative regimen containing low-dose TBI.

Authors:  H J Im; K N Koh; J K Suh; S W Lee; E S Choi; S Jang; S W Kwon; C-J Park; J J Seo
Journal:  Bone Marrow Transplant       Date:  2016-05-09       Impact factor: 5.483

3.  No Improvement of Survival for Alveolar Rhabdomyosarcoma Patients After HLA-Matched Versus -Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Compared to Standard-of-Care Therapy.

Authors:  Sebastian Johannes Schober; Erika Hallmen; Florian Reßle; Hendrik Gassmann; Carolin Prexler; Angela Wawer; Irene von Luettichau; Ruth Ladenstein; Bernarda Kazanowska; Gustaf Ljungman; Felix Niggli; Olli Lohi; Julia Hauer; Bernd Gruhn; Thomas Klingebiel; Peter Bader; Stefan Burdach; Peter Lang; Monika Sparber-Sauer; Ewa Koscielniak; Uwe Thiel
Journal:  Front Oncol       Date:  2022-05-10       Impact factor: 5.738

4.  No difference in survival after HLA mismatched versus HLA matched allogeneic stem cell transplantation in Ewing sarcoma patients with advanced disease.

Authors:  U Thiel; S J Schober; A Ranft; H Gassmann; S Jabar; K Gall; I von Lüttichau; A Wawer; E Koscielniak; M A Diaz; M Ussowicz; I Kazantsev; B Afanasyev; M Merker; T Klingebiel; A Prete; B Gruhn; P Bader; H Jürgens; U Dirksen; R Handgretinger; S Burdach; P Lang
Journal:  Bone Marrow Transplant       Date:  2021-01-29       Impact factor: 5.483

5.  In vitro immunotherapy potency assays using real-time cell analysis.

Authors:  Fabio Cerignoli; Yama A Abassi; Brandon J Lamarche; Garret Guenther; David Santa Ana; Diana Guimet; Wen Zhang; Jing Zhang; Biao Xi
Journal:  PLoS One       Date:  2018-03-02       Impact factor: 3.240

6.  Donor lymphocyte infusions in adolescents and young adults for control of advanced pediatric sarcoma.

Authors:  Sebastian J Schober; Irene von Luettichau; Angela Wawer; Maximilian Steinhauser; Christoph Salat; Wolfgang Schwinger; Marek Ussowicz; Petar Antunovic; Luca Castagna; Hans-Jochem Kolb; Stefan E G Burdach; Uwe Thiel
Journal:  Oncotarget       Date:  2018-04-27

Review 7.  Prospects for NK Cell Therapy of Sarcoma.

Authors:  Mieszko Lachota; Marianna Vincenti; Magdalena Winiarska; Kjetil Boye; Radosław Zagożdżon; Karl-Johan Malmberg
Journal:  Cancers (Basel)       Date:  2020-12-11       Impact factor: 6.639

Review 8.  Enhancing Natural Killer Cell Targeting of Pediatric Sarcoma.

Authors:  Natacha Omer; Wayne Nicholls; Bronte Ruegg; Fernando Souza-Fonseca-Guimaraes; Gustavo Rodrigues Rossi
Journal:  Front Immunol       Date:  2021-11-04       Impact factor: 7.561

9.  T-cell replete haploidentical stem cell transplantation with low dose anti-thymocyte globulin for relapsed/refractory Ewing sarcoma family tumors.

Authors:  Hideki Sano; Kazuhiro Mochizuki; Shogo Kobayashi; Yoshihiro Ohara; Nobuhisa Takahashi; Shingo Kudo; Kazuhiko Ikeda; Hitoshi Ohto; Atsushi Kikuta
Journal:  Cancer Rep (Hoboken)       Date:  2021-07-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.